The estimated Net Worth of Daniel P Florin is at least $5.26 Million dollars as of 12 July 2021. Mr. Florin owns over 2,500 units of Atricure Inc stock worth over $202,611 and over the last 9 years he sold ATRC stock worth over $4,879,500. In addition, he makes $178,798 as Independent Director at Atricure Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Florin ATRC stock SEC Form 4 insiders trading
Daniel has made over 10 trades of the Atricure Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 2,500 units of ATRC stock worth $100,000 on 12 July 2021.
The largest trade he's ever made was exercising 16,225 units of Atricure Inc stock on 24 June 2017 worth over $436,453. On average, Daniel trades about 3,167 units every 82 days since 2015. As of 12 July 2021 he still owns at least 7,532 units of Atricure Inc stock.
You can see the complete history of Mr. Florin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Daniel Florin biography
Daniel P. Florin serves as Independent Director of the Company. Mr. Florin has served as one of our directors since December 2019. Mr. Florin most recently served as Executive Vice President at Zimmer Biomet Holdings, a publicly-held global leader in musculoskeletal healthcare until March 2020. He was appointed to his position in July 2019 upon announcing his intention to retire from the company. Previously he served as Executive Vice President and Chief Financial Officer of the company from June 2015 to July 2019. In addition, he served as Interim Chief Executive Officer of the company from July 2017 to December 2017. Prior to working at Zimmer Biomet, Mr. Florin was Chief Financial Officer for Biomet, Inc. until the company merged with Zimmer, Inc. and became Zimmer Biomet Holdings. Prior to working at Biomet, he held various roles at Boston Scientific, Inc., CR Bard, Inc. and Deloitte & Touche, LLP. Mr. Florin has served on the Board of Directors of Pulmonx since January 2020. Mr. Florin received an undergraduate degree from the University of Notre Dame and earned his M.B.A. from Boston University Executive MBA program.
What is the salary of Daniel Florin?
As the Independent Director of Atricure Inc, the total compensation of Daniel Florin at Atricure Inc is $178,798. There are 11 executives at Atricure Inc getting paid more, with Michael Carrel having the highest compensation of $5,829,780.
How old is Daniel Florin?
Daniel Florin is 55, he's been the Independent Director of Atricure Inc since 2019. There are 7 older and 5 younger executives at Atricure Inc. The oldest executive at Atricure Inc is Sven Wehrwein, 69, who is the Independent Director.
What's Daniel Florin's mailing address?
Daniel's mailing address filed with the SEC is C/O PULMONX CORPORATION, 700 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063.
Insiders trading at Atricure Inc
Over the last 19 years, insiders at Atricure Inc have traded over $52,789,242 worth of Atricure Inc stock and bought 666,621 units worth $5,937,195 . The most active insiders traders include Scott William Drake, Group I, Llc Donoghue Danie..., and Management Group Viii L L C.... On average, Atricure Inc executives and independent directors trade stock every 24 days with the average trade being worth of $548,410. The most recent stock trade was executed by Maggie Yuen on 15 August 2024, trading 3,500 units of ATRC stock currently worth $84,245.
What does Atricure Inc do?
atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.
What does Atricure Inc's logo look like?
Complete history of Mr. Florin stock trades at Atricure Inc, Zimmer Biomet Inc, and Pulmonx Corp
Atricure Inc executives and stock owners
Atricure Inc executives and other stock owners filed with the SEC include:
-
Michael Carrel,
President, Chief Executive Officer, Director -
Douglas Seith,
Chief Operating Officer -
Salvatore Privitera,
Chief Technology Officer -
Justin Noznesky,
Senior Vice President, Marketing and Business Development -
Scott Drake,
Independent Chairman of the Board -
Sven Wehrwein,
Independent Director -
Mark Lanning,
Independent Director -
B. Kristine Johnson,
Independent Director -
Robert White,
Independent Director -
Regina Groves,
Independent Director -
Mark Collar,
Independent Director -
Karen Prange,
Independent Director -
Daniel Florin,
Independent Director -
Angela Wirick,
Chief Financial Officer -
Shlomo Nachman,
Director -
Karen P Robards,
Director -
Elizabeth D Krell,
Director -
Richard M Johnston,
Director -
Michael D Hooven,
Director -
Andrew L Lux,
V.P. & Chief Operating Officer -
Group I, Llc Murphy Michael...,
-
M. Andrew Wade,
CFO -
Tonya Austin,
Chief Human Resources Officer -
Deborah L Morley,
VP Clinical Affairs -
Lee R Wrubel,
Director -
Maureen Shaffer,
Vice President Marketing -
Jon A Sherman,
VP Product Development -
Elsa Chi Abruzzo,
VP; Regulatory&ClinicalAffairs -
Alan L Kaganov,
Director -
Richard S Walsh,
Vice President; Sales -
Management Group Viii L L C...,
-
Management Group Viii L L C...,
-
Stephen S Cambridge,
Vice President; Sales -
Management Group Viii L L C...,
-
Thomas J Etergino,
Vice President and CFO -
Norman R Weldon,
Director -
Patricia J Kennedy,
VP, GM, International -
James L Lucky,
VP; QA & Healthcare Compliance -
Management Group Viii L L C...,
-
David J Drachman,
President and CEO -
Richard Mcamden Partners St...,
-
Richard Mcamden Partners St...,
-
Donald C Harrison,
Director -
Group I, Llc Donoghue Danie...,
-
Stewart W Strong,
Vice President US Sales -
Management Group Viii L L C...,
-
Frederick Preiss,
Vice President; Operations -
Julie A Piton,
VP and CFO -
Deborah H Telman,
Director -
Karl S. Dahlquist,
Chief Legal Officer -
Vinayak Doraiswamy,
Chief Scientific Officer -
Maggie Yuen,
Director -
Deborah Lee Yount,
Chief Human Resources Officer